AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2012
Aug 10, 2012
30016_dirs_2012-08-10_d1c3c473-ea9e-41f4-9f7a-ab7ef09b64b7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2012-08-08
Reporting Person: RAINES MERILEE (Executive VP & CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-08-08 | Common Stock | M | 2032 | $38.3350 | Acquired | 173053 | Direct |
| 2012-08-08 | Common Stock | M | 5694 | $17.1350 | Acquired | 178747 | Direct |
| 2012-08-08 | Common Stock | S | 6906 | $88.7711 | Disposed | 171841 | Direct |
| 2012-08-08 | Common Stock | S | 820 | $89.4341 | Disposed | 171021 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-08-08 | Non-Qualified Stock Options (right to buy) | $38.3350 | M | 2032 | Disposed | 2013-02-13 | Common Stock (2032) | Direct |
| 2012-08-08 | Non-Qualified Stock Options (right to buy) | $17.1350 | M | 5694 | Disposed | 2014-02-06 | Common Stock (5694) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 13430 | Indirect |
Footnotes
F1: The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 04/26/2012.
F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $88.30 to $89.29, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
F3: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $89.30 to $89.55, inclusive.
F4: Grant of options to buy shares of common stock becomes exercisable as to 2,960 shares on 02/14/2007, 02/14/2008, 02/14/2009, and 02/14/2010, and the remaining 352 shares on 02/14/2011.
F5: Grant of options to buy shares of common stock becomes exercisable as to 8,000 shares on 02/06/2004, 02/06/2005, 02/06/2006, and 02/06/2007, and the remaining 2,164 shares on 02/06/2008.